ATE455791T1 - T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon - Google Patents

T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Info

Publication number
ATE455791T1
ATE455791T1 AT06709221T AT06709221T ATE455791T1 AT E455791 T1 ATE455791 T1 AT E455791T1 AT 06709221 T AT06709221 T AT 06709221T AT 06709221 T AT06709221 T AT 06709221T AT E455791 T1 ATE455791 T1 AT E455791T1
Authority
AT
Austria
Prior art keywords
individuals
majority
epstein
epitopes
applications
Prior art date
Application number
AT06709221T
Other languages
English (en)
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Bernard Maillere
Olivier Morales
Gaetan Munier
Original Assignee
Centre Nat Rech Scient
Commissariat Energie Atomique
Univ Lille Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Commissariat Energie Atomique, Univ Lille Ii filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE455791T1 publication Critical patent/ATE455791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06709221T 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon ATE455791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (1)

Publication Number Publication Date
ATE455791T1 true ATE455791T1 (de) 2010-02-15

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06709221T ATE455791T1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Country Status (8)

Country Link
US (1) US20090130134A1 (de)
EP (1) EP1861418B1 (de)
JP (1) JP4972562B2 (de)
AT (1) ATE455791T1 (de)
CA (1) CA2596929C (de)
DE (1) DE602006011859D1 (de)
FR (1) FR2881746B1 (de)
WO (1) WO2006082313A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3971454B2 (ja) * 1993-10-29 2007-09-05 ザ トラスティーズ オブ ボストン ユニバーシティ 抗新生物剤としての酪酸、酪酸塩、および誘導体の生理学的に安定な組成物
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2083856T1 (sl) 2007-08-15 2011-02-28 Circassia Ltd Peptidi za desenzibilizacijo proti alergijam
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
US10576144B2 (en) 2013-06-28 2020-03-03 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
SG11201704962WA (en) * 2014-12-23 2017-07-28 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
CN104491857B (zh) * 2014-12-24 2018-08-31 深圳市中美康士生物科技有限公司 一种用于免疫治疗ebv相关疾病的抗原组合物、生物制剂及其制备方法
CA3014515A1 (en) 2016-02-26 2017-08-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN116693695A (zh) 2017-02-12 2023-09-05 百欧恩泰美国公司 基于hla的方法和组合物及其用途
WO2019123169A1 (en) * 2017-12-20 2019-06-27 Glaxosmithkline Biologicals Sa Epstein-barr virus antigen constructs
WO2020132586A1 (en) 2018-12-21 2020-06-25 Neon Therapeutics, Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US20220226322A1 (en) 2019-05-31 2022-07-21 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
EP0770090A1 (de) * 1994-07-13 1997-05-02 Cornell Research Foundation, Inc. Protein des epstein-barr virus kernantigen 1 und seine expression und anreicherung
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
EP1233781A1 (de) * 1999-11-24 2002-08-28 Oklahoma Medical Research Foundation Testverfahren und therapien für latenter viraler infektion
EP1229043A1 (de) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptiden abgeleitet VON Epstein Barr virus (EBV) Proteine LMP1, LMP2 und BARF1
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
WO2004007536A2 (en) * 2002-07-16 2004-01-22 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
TW200416043A (en) * 2002-11-07 2004-09-01 Queensland Inst Med Res Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
US20090130134A1 (en) 2009-05-21
JP2008529486A (ja) 2008-08-07
CA2596929A1 (fr) 2006-08-10
FR2881746A1 (fr) 2006-08-11
EP1861418B1 (de) 2010-01-20
WO2006082313A3 (fr) 2007-01-11
WO2006082313A2 (fr) 2006-08-10
JP4972562B2 (ja) 2012-07-11
EP1861418A2 (de) 2007-12-05
CA2596929C (fr) 2015-12-29
DE602006011859D1 (de) 2010-03-11
FR2881746B1 (fr) 2007-04-13

Similar Documents

Publication Publication Date Title
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
MX2019003768A (es) Moleculas de enlace especificas de hpv.
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MX2011000767A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EA201390806A1 (ru) Конструкция пептидного каркаса
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
EA201170353A1 (ru) Антитела против гепатита с и их применение
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2009042895A3 (en) Reagents for inducing an immune response
ECSP10010327A (es) Péptidos del fviii y su uso para hemofílicos tolerantes
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
EA201290792A1 (ru) Пептиды для вакцины против аллергии на березу
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2005023849A3 (en) Antigenic peptides of rabies virus and uses thereof
WO2010080188A3 (en) Epitope targeted anthrax vaccine
WO2007025276A3 (en) Use of hiv envelope/ cd4 complexes as immunogenic complexes for the generation of antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties